Fundraising Fox
/Companies
Sign in

Delphi Diagnostics

Austin, US · Founded 2016 · Texas corporation · 2 known investors

Find your way into Delphi Diagnostics

Sign up to see every warm intro you have to Delphi Diagnostics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Delphi Diagnostics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Delphi Diagnostics develops genomic diagnostic tests for breast cancer that measure endocrine transcriptional activity to help healthcare providers personalize treatment decisions. Its tests target Stage II-III, HR+, HER2- breast cancer patients to identify who will benefit from dose-intense chemotherapy and to inform recurrence risk and prognosis.

BiotechHealthtech

Founders & leadership

WC
William CreechExecutive

Investors · 2

DigitalDx Ventureslisted by DigitalDx VenturesMenlo Park

How we know: DigitalDx Ventures's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$470K disclosed across 1 of 2 rounds · 2017–2021

▶$50MofferedJun 2021 · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Winz CasagrandeExecutive Officer, Director
  • Fidel ReijerseDirector
  • Paul SmithDirector
Offering amount
$50M
Incorporated
Corporation, Texas, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$470KraisedJan 2017 · 3 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • William CreechExecutive Officer
Offering amount
$1M
Amount sold
$470K
First sale
Jan 2017
Incorporated
Corporation, Texas, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

DelphiDelphi is an AI-powered assistant platform that helps venture capitalists scale their investment operations by automating deal screening, founder communication, and thought leadership distribution. The platform trains on a VC's own content and investment thesis to provide personalized feedback to founders and manage deal flow 24/7.
Delfi DiagnosticsDELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening. The test offers an alternative to low-dose CT imaging for patients meeting USPSTF criteria and is made available to health systems, primary care providers, and lung screening programs.
Delphia TherapeuticsDelphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies. It focuses on oncology drug discovery and clinical development.

Companies working in the same space as Delphi Diagnostics.

In the news

Investors - Delphi Diagnosticsdelphi-diagnostics.com · Apr 2025

Frequently asked questions

What does Delphi Diagnostics do?
Delphi Diagnostics develops genomic diagnostic tests for breast cancer that measure endocrine transcriptional activity to help healthcare providers personalize treatment decisions. Its tests target Stage II-III, HR+, HER2- breast cancer patients to identify who will benefit from dose-intense chemotherapy and to inform recurrence risk and prognosis.
Who are Delphi Diagnostics's investors?
Delphi Diagnostics's investors include aVenture, DigitalDx Ventures.
How much funding has Delphi Diagnostics raised?
Delphi Diagnostics has disclosed $470K raised across 1 of its 2 known rounds.
Where is Delphi Diagnostics headquartered?
Delphi Diagnostics is headquartered in Austin, US.